These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 35696531

  • 1. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F, Wu L, Yin L, Shi H, Gu Y, Xing N.
    Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, Lee JH, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW.
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L, Shen M, Chen X, Zhu R, Yang DR, Tsai Y, Keng PC, Chen Y, Lee SO.
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [Abstract] [Full Text] [Related]

  • 6. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C.
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34+ cells and PD-L1 CAR-modified UCB-CD34+-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells.
    Ghaedrahmati F, Akbari V, Seyedhosseini-Ghaheh H, Esmaeil N.
    Stem Cell Res Ther; 2024 Aug 13; 15(1):257. PubMed ID: 39135206
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X, Sun Z, Yuan Q, Hou W, Liang Q, Wang Y, Mo W, Wang H, Yu M.
    Invest New Drugs; 2021 Feb 13; 39(1):34-51. PubMed ID: 32772342
    [Abstract] [Full Text] [Related]

  • 11. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE, Kim SE, Keam B, Park HR, Kim S, Kim M, Kim TM, Doh J, Kim DW, Heo DS.
    J Immunother Cancer; 2020 Aug 13; 8(2):. PubMed ID: 32830112
    [Abstract] [Full Text] [Related]

  • 12. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A, Sun Y, Wang S, Du J, Gao X, Yuan Y, Zhao L, Yang Y, Xu L, Lei Y, Duan L, Xu C, Ma L, Wang J, Hu G, Chen H, Wang Q, Hu L, Zhang B.
    Cytotherapy; 2020 Dec 13; 22(12):734-743. PubMed ID: 32684339
    [Abstract] [Full Text] [Related]

  • 13. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM, Penna A, Fracasso G, Carpanese D, Dalla Pietà A, Barbieri V, Zuccolotto G, Rosato A.
    Cells; 2020 Jun 02; 9(6):. PubMed ID: 32498368
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Tang M, Gao S, Zhang L, Liu B, Li J, Wang Z, Zhang W.
    Prostate; 2020 Jul 02; 80(10):742-752. PubMed ID: 32449811
    [Abstract] [Full Text] [Related]

  • 15. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, Wang R, Zhu L, Meng Y, Hu C, Liang H, Lin X, Zhu K, Chen G, Luo KQ, Di L, Zhao Q.
    J Hematol Oncol; 2021 Jan 29; 14(1):21. PubMed ID: 33514401
    [Abstract] [Full Text] [Related]

  • 16. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J.
    Cancer Immunol Res; 2015 Oct 29; 3(10):1148-1157. PubMed ID: 26014098
    [Abstract] [Full Text] [Related]

  • 17. CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis.
    Sun D, Tan L, Chen Y, Yuan Q, Jiang K, Liu Y, Xue Y, Zhang J, Cao X, Xu M, Luo Y, Xu Z, Xu Z, Xu W, Shen M.
    J Exp Clin Cancer Res; 2024 Jul 22; 43(1):202. PubMed ID: 39034411
    [Abstract] [Full Text] [Related]

  • 18. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer.
    Wang F, Liu S, Liu F, Xu T, Ma J, Liang J, Wang J, Liu D, Yang F, Li J, Xing N.
    Cancer Lett; 2023 Aug 01; 568():216300. PubMed ID: 37414394
    [Abstract] [Full Text] [Related]

  • 19. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
    Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP, Padget MR, Abdul Sater H, Lee JH, Soon-Shiong P, Gulley J, Schlom J, Hodge JW, Allen CT.
    Elife; 2020 Jul 07; 9():. PubMed ID: 32633234
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
    Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus PT.
    Cytotherapy; 2023 Feb 07; 25(2):148-161. PubMed ID: 36396553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.